Table 1 The demographic, clinical, and laboratory characteristics of the patients and controls
From: The role of M1/M2 macrophage polarization in primary Sjogren’s syndrome
pSS (n = 30) | HC (n = 30) | non-pSS (n = 10) | |
|---|---|---|---|
Female, N (%) | 30 (100) | 30 (100) | 10 (100) |
Age (years), mean ± SD | 43.4 ± 12.2 | 41.1 ± 9.9 | 46.6 ± 12.8 |
Duration of sicca symptoms, median (IQR) years | 3.0 (1.5-8.0) | / | 2.5 (1.0-6.5) |
Oral dryness (VAS,1–10), median (IQR) | 5.5 (2.5-6.0) | / | 2.0 (0-4.5) |
Ocular dryness (VAS,1–10), median (IQR) | 3.0 (1.0-5.5) | / | 1.5 (0-3.5) |
Labial salivary gland biopsies, N | 20 | / | 10 |
Grade1, N | 0 | / | 7 |
Grade2, N | 0 | / | 3 |
Grade3, N | 9 | / | 0 |
Grade4, N | 11 | / | 0 |
IgG (g/L), median (IQR) | 18.5 (15.3–23.8) | / | 10.8 (9.3–11.8) |
C3 (g/L), mean ± SD | 0.95 ± 0.23 | / | 1.01 ± 0.29 |
C4 (g/L), mean ± SD | 209.5 ± 92.7 | / | 205.1 ± 83.5 |
ESR (mm/h), median (IQR) | 27 (13–48) | / | 12 (5–18) |
CRP (mg/L), median (IQR) | 3.9 (3.1–7.5) | / | 3.6 (2.8–7.3) |
RF positivity, N (%) | 14 (46.7) | / | 1 (10.0) |
Anti-SSA positivity, N (%) | 25 (83.3) | / | 0 (0) |
Anti-SSB positivity, N(%) | 6 (20.0) | / | 0 (0) |
B cell, %. mean ± SD | 17.0 ± 7.2 | / | / |
ESSDAI score, median (IQR) | 3 (1–4) | / | / |
Organ involvement | |||
Interstitial lung disease, N (%) | 5 (16.7) | / | / |
Haematologic, N (%) | 6 (20.0) | / | / |
Renal, N (%) | 2 (6.7) | / | / |
Parotitis, N (%) | 5 (16.7) | / | / |
Arthritis, N (%) | 4 (13.3) | / | / |
Peripheral neuropathy, N (%) | 1 (3.3) | / | / |